Rhian Hopkins
Graduate Research Assistant
rh530@exeter.ac.uk
Publications
Journal articles
Hopkins R, Bailey SER, Hamilton W, Shephard E (In Press). Microcytosis as a risk marker of cancer in primary care: a cohort study using electronic patient records. British Journal of General Practice
Hopkins R, Young K, Thomas N, Godwin J, Raja D, Mateen B, Challen R, Vollmer S, Shields B, McGovern A, et al (In Press). Risk factor associations for severe Covid-19, influenza, and pneumonia in people with diabetes to inform future pandemic preparations: UK population-based cohort study. BMJ Open
Decina CS, Hopkins R, Bowden J, Shields BM, Lawlor DA, Warrington NM, Evans DM, Freathy RM, Beaumont RN (2023). Investigating a possible causal relationship between maternal serum urate concentrations and offspring birthweight: a Mendelian randomization study. Int J Epidemiol, 52(1), 178-189. Abstract. Author URL.
Cardoso P, Young KG, Nair ATN, Hopkins R, McGovern AP, Haider E, Karunaratne P, Donnelly L, Mateen BA, Sattar N, et al (2023). Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Abstract.
Young KG, Hopkins R, Shields BM, Thomas NJ, McGovern AP, Dennis JM (2023). Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy. Abstract.
Conferences
Young KG, McGovern AP, Hopkins R, Raya D, Pearson ER, Hattersley AT, Jones AG, Shields BM, Dennis JM (2023). Precision medicine in type 2 diabetes: Individual-level prediction of heart failure risk accurately identifies people most likely to benefit with SGLT2-inhibitors. Author URL.
Cardoso P, Young KG, Hopkins R, Raya D, Jones AG, Pearson ER, Hattersley AT, Shields BM, McKinley TJ, Dennis JM, et al (2023). Precision medicine in type 2 diabetes: Simple clinical characteristics alter the glucose-lowering efficacy of SGLT2-inhibitors and GLP-1 receptor agonists and can determine optimal therapy choice. Author URL.
Dennis JM, Young K, Cardoso P, Hopkins R, Pearson E, Hattersley A, McKinley T, Jones A, Shields BM (2023). Precision medicine in type 2 diabetes: validation of an treatment selection model for SGLT2-inhibitor and DPP4-inhibitor therapies in people of non-white ethnicity. Author URL.
Hopkins R, Young KG, Thomas NJ, Jones AG, Hattersley AT, Shields BM, Dennis JM, McGovern AP (2023). Treatment outcomes with oral anti-hyperglycaemic therapy for people with diabetes secondary to chronic pancreatitis: matched population based cohort study. Author URL.
Young KG, Hopkins R, Thomas NJ, Shields BM, Dennis JM, McGovern AP (2022). Current rates of sodium-glucose link transporter 2 inhibitors (SGLT2i) prescribing in type 2 diabetes show no evidence of prioritisation in those with cardiovascular disease and heart failure. Author URL.
Hopkins R, Godwin J, Young KG, Mateen BA, Vollmer SJ, Thomas NJ, Shields BM, McGovern AP, Dennis JM (2022). In people with type 2 diabetes most risk factors for covid-19 mortality are shared with pneumonia, however ethnicity related risk is very different. Author URL.
Hopkins R, Young KG, Godwin J, Raja D, Thomas NJ, Shields BM, Dennis JM, McGovern AP (2022). Modifiable risk factors including HbA<sub>1c</sub> and BMI are consistently associated with severe influenza, pneumonia, and Covid-19 infection outcomes in people with type 2 diabetes. Author URL.
Young KG, McGovern AP, Hopkins R, Raya D, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Shields BM, et al (2022). Precision medicine in type 2 diabetes: integrating trial and real-world evidence can provide accurate estimates of heart failure benefit when initiating SGLT2-inhibitors. Author URL.
